These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2033771)

  • 1. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis.
    Jordan TJ; Lewit EM; Montgomery RL; Reichman LB
    JAMA; 1991 Jun; 265(22):2987-91. PubMed ID: 2033771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy.
    Selwyn PA; Sckell BM; Alcabes P; Friedland GH; Klein RS; Schoenbaum EE
    JAMA; 1992 Jul 22-29; 268(4):504-9. PubMed ID: 1619742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world.
    Sterling TR; Brehm WT; Moore RD; Chaisson RE
    Int J Tuberc Lung Dis; 1999 Mar; 3(3):248-54. PubMed ID: 10094327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoniazid preventive therapy in areas of high isoniazid resistance.
    Sterling TR; Brehm WT; Frieden TR
    Arch Intern Med; 1995 Aug 7-21; 155(15):1622-8. PubMed ID: 7618985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Decision regarding chemoprophylaxis with isoniazid in patients using parenteral drugs and infected with HIV].
    Sánchez Fuentes D; Barragán Casas JM; Garcinuño Jiménez MA; Martín Casado M; Martín Marcos M
    Rev Clin Esp; 1994 Feb; 194(2):81-6. PubMed ID: 8008944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: revised recommendations. Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1997 Sep; 46(RR-15):1-10. PubMed ID: 9332982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis.
    Rose DN; Schechter CB; Fahs MC; Silver AL
    Am J Prev Med; 1988; 4(2):102-9. PubMed ID: 3134928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
    Samandari T; Agizew TB; Nyirenda S; Tedla Z; Sibanda T; Shang N; Mosimaneotsile B; Motsamai OI; Bozeman L; Davis MK; Talbot EA; Moeti TL; Moffat HJ; Kilmarx PH; Castro KG; Wells CD
    Lancet; 2011 May; 377(9777):1588-98. PubMed ID: 21492926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors.
    Rose DN; Schechter CB; Silver AL
    JAMA; 1986 Nov; 256(19):2709-13. PubMed ID: 3773178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoniazid preventive therapy for tuberculosis. Decision analysis considering ethnicity and gender.
    Jordan TJ; Lewit EM; Reichman LB
    Am Rev Respir Dis; 1991 Dec; 144(6):1357-60. PubMed ID: 1741549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
    Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
    Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors.
    Colice GL
    Arch Intern Med; 1990 Dec; 150(12):2517-22. PubMed ID: 2244768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
    Salpeter SR; Sanders GD; Salpeter EE; Owens DK
    Ann Intern Med; 1997 Dec; 127(12):1051-61. PubMed ID: 9412307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
    Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
    AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk for developing tuberculosis among anergic patients infected with HIV.
    Moreno S; Baraia-Etxaburu J; Bouza E; Parras F; Pérez-Tascón M; Miralles P; Vicente T; Alberdi JC; Cosín J; López-Gay D
    Ann Intern Med; 1993 Aug; 119(3):194-8. PubMed ID: 8100693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive medicine for HIV-infected patients: an analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patients.
    Rose DN; Schechter CB; Sacks HS
    J Gen Intern Med; 1992; 7(6):589-94. PubMed ID: 1360493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid for the tuberculin reactor: take it or leave it.
    Tsevat J; Taylor WC; Wong JB; Pauker SG
    Am Rev Respir Dis; 1988 Jan; 137(1):215-20. PubMed ID: 3276255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration.
    Johnson JL; Nyole S; Okwera A; Whalen CC; Nsubuga P; Pekovic V; Huebner R; Wallis RS; Mugyenyi PN; Mugerwa RD; Ellner JJ
    Am J Respir Crit Care Med; 1998 Dec; 158(6):1790-6. PubMed ID: 9847269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tuberculin screening and isoniazid preventive therapy program in an inner-city population.
    Bock NN; Metzger BS; Tapia JR; Blumberg HM
    Am J Respir Crit Care Med; 1999 Jan; 159(1):295-300. PubMed ID: 9872853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis.
    MMWR Recomm Rep; 1991 Apr; 40(RR-5):27-32. PubMed ID: 2034206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.